Literature DB >> 12681004

A proton magnetic resonance spectroscopy study of metabolites in the occipital lobes in epilepsy.

Robert J Simister1, Mary A McLean, Gareth J Barker, John S Duncan.   

Abstract

PURPOSE: gamma-Amino butyric acid (GABA) and glutamate, respectively the principal inhibitory and excitatory neurochemicals in the brain, are visible to proton magnetic resonance spectroscopy (MRS). We report a study of GABA+ (GABA plus homocarnosine) and GLX (glutamate plus glutamine) concentrations in the occipital lobes in patients with idiopathic generalised epilepsy (IGE) and in patients with occipital lobe epilepsy (OLE).
METHODS: Fifteen patients with IGE, 15 patients with OLE, and 15 healthy volunteers were studied. A single voxel was prescribed in the occipital lobes for each subject. PRESS localised short-echo-time MRS was performed to measure GLX by using LCModel. A double quantum GABA filter was used to measure GABA+. Segmented T1-weighted images gave the tissue composition of the prescribed voxel.
RESULTS: Grey-matter proportion, GLX, and GABA+ were all elevated in IGE. However, analysis using grey-matter proportion as a covariable showed no significant group differences. No correlation was observed between GABA+ concentration and either seizure frequency or time since last seizure.
CONCLUSIONS: GLX and GABA+ were elevated in IGE. Elevated grey-matter content in the IGE group despite normal MRI appearance can be expected to account for some or all of this observed elevation of GLX and GABA+. GABA+ concentration did not correlate with seizure control or duration since most recent seizure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681004     DOI: 10.1046/j.1528-1157.2003.19102.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  In vivo magnetic resonance spectroscopy of GABA: a methodological review.

Authors:  Nicolaas A J Puts; Richard A E Edden
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2011-06-12       Impact factor: 9.795

2.  Magnetic resonance spectroscopy in generalized epilepsy.

Authors:  William H Theodore
Journal:  Epilepsy Curr       Date:  2004 Sep-Oct       Impact factor: 7.500

3.  In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects.

Authors:  Ruth L O'Gorman; Lars Michels; Richard A Edden; James B Murdoch; Ernst Martin
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

Review 4.  Proton MR Spectroscopy of Pediatric Brain Disorders.

Authors:  Stefan Blüml; Alexander Saunders; Benita Tamrazi
Journal:  Diagnostics (Basel)       Date:  2022-06-14

5.  Investigation of glutamine and GABA levels in patients with idiopathic generalized epilepsy using MEGAPRESS.

Authors:  Fahmida A Chowdhury; Ruth L O'Gorman; Lina Nashef; Robert D Elwes; Richard A Edden; James B Murdoch; Gareth J Barker; Mark P Richardson
Journal:  J Magn Reson Imaging       Date:  2014-03-03       Impact factor: 4.813

6.  Increased thalamus levels of glutamate and glutamine (Glx) in patients with idiopathic generalised epilepsy.

Authors:  G Helms; C Ciumas; S Kyaga; I Savic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

7.  Connecting occipital alpha band peak frequency, visual temporal resolution, and occipital GABA levels in healthy participants and hepatic encephalopathy patients.

Authors:  Thomas J Baumgarten; Julia Neugebauer; Georg Oeltzschner; Nur-Deniz Füllenbach; Gerald Kircheis; Dieter Häussinger; Joachim Lange; Hans-Jörg Wittsack; Markus Butz; Alfons Schnitzler
Journal:  Neuroimage Clin       Date:  2018-08-09       Impact factor: 4.881

8.  Two-Dimensional Proton Magnetic Resonance Spectroscopy versus J-Editing for GABA Quantification in Human Brain: Insights from a GABA-Aminotransferase Inhibitor Study.

Authors:  Andrew P Prescot; James J Prisciandaro; Steven R Miller; Gary Ingenito; Douglas G Kondo; Perry F Renshaw
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.